Tela Bio’s 2026 Guidance, Hiring Timelines, and Strategy Shifts Don’t Match

Date of Call: Mar 24, 2026

Financials Results

• Revenue: $80.3M for full year, up 16% YOY; Q4: $20.9M, up 18% YOY
• Gross Margin: 66% for Q4 and 68% for full year, compared to 64% and 67% in prior year periods, respectively
• Operating Margin: Operating loss of $6.6M in Q4 and $33.8M for full year, compared to $8.4M and $34.1M in prior year periods

Guidance:

• Revenue for full year 2026 expected to grow at least 8% over 2025.
• Q1 2026 revenue expected to be approximately $18.5 million.
• Operating loss and net loss expected to decline for both the year and over the quarters, with a step-up likely from Q4 2025 to Q1 2026.
• Expect similar prior-year quarterly cadence, amplified by new sales reps ramping productivity over 6-9 months.

Business Commentary:

Revenue Growth and Commercial Reorganization:

• TELA Bio reported revenue of $80.3 million for the full year 2025, a 16% increase year-over-year.
• The growth was driven by strategic changes in the commercial organization, including a significant rebuild of the U.S. commercial team, strong performance in Europe, and the continued adoption of product lines like IHR, LPR, and LIQUIFIX.

Product Innovation and Portfolio Expansion:

• The company launched OviTex LTR in 2025, which contributed to the growth of the OviTex product line.
• This innovation, along with the anticipation of additional product launches in 2026, is aimed at driving greater market share gains.

Sales Force Restructuring and Performance:

• TELA Bio achieved its 76 territory manager target early and currently has 88 quota-carrying territory managers, with more hires imminent.
• The strategic investment in high-caliber sales talent and the redesign of the sales force structure are intended to drive durable and predictable growth.

European Market Performance:

• European sales accounted for 15% of total revenue, or $12.1 million, in 2025, a 17% increase from the previous year.
• Growth in Europe is attributed to strong traction in key markets like the U.K. and the Netherlands, with a focus on expanding presence in continental Europe.

Focus on Contract Execution and Customer Education:

• The company is shifting its sales and marketing focus to emphasize the mechanism of action of OviTex and is increasing spending on customer education and training events.
• This strategy aims to improve forecasting accuracy and achieve sustainable growth by deepening penetration in target accounts and enhancing surgeon awareness.

Sentiment Analysis:

Overall Tone: Positive

• "We enter 2026 with the largest, most effective field team in the company’s history." "Demand for our products remains strong." "We are confident that we will grow revenue over 2025 by at least 8%." "We have a purposeful investment plan to expand our presence within continental Europe and see it as a meaningful contributor to growth in the coming years."

Q&A:

• Question from Caitlin Cronin (Canaccord Genuity): Starting off with the fiscal year top line guidance for at least 8%, just a little bit more color on why it was below what you guys noted on the Q3 call, and if you could provide some cadence to that guidance for the year, that would be great.
  Response: Guidance was set prudently due to significant organizational changes, new reps ramping up, and contracting complexities; cadence expected similar to prior years with quarterly steps up, amplified by new reps becoming productive in 6-9 months.

• Question from Caitlin Cronin (Canaccord Genuity): How many IDNs or GPOs have you transferred to, you know, really recategorize OviTex? What are your expectations to continue doing that this year?
  Response: Focus is on execution of existing contracts; 2026 is an execution year to translate signed agreements into patient volume and revenue, with continued pursuit of new opportunities like Vizient.

• Question from Frank Takkinen (Lake Street Capital Markets): Was just curious if there was anything else specific to call out with Q1. I know typically the seasonality is kind of up a few% or down a few%... just the double-digit down quarter-over-quarter.
  Response: Q1 includes a planned territory restructuring to smaller, more efficient areas which may cause some loss in peripheral hospitals, and external factors like a blizzard impacting elective procedures; guidance reflects prudence.

• Question from Frank Takkinen (Lake Street Capital Markets): As we think about exiting this period where we’re maybe returning to a steady state growth rate, how do you view the steady state growth profile of TELA over a longer period of time?
  Response: Expect to significantly outgrow the mid-single-digit market, targeting double-digit plus growth, with units already showing strong growth; comprehensive changes aim to restore this trajectory.

• Question from Frank Takkinen (Lake Street Capital Markets): What’s your latest thought on how we should think about when ASPs in hernia could start to flatten out and stabilize?
  Response: Mix shift towards more inguinal and hiatal procedures (smaller pieces) will pressure ASPs, but this is offset by higher unit volume and growth in robotic/laparoscopic procedures; long-term resorbable product may open new cases.

• Question from Michael Sarcone (Jefferies): Just trying to get a better sense for, you know, what changed... Did anything else change... around expected rep productivity ramp or anything like that? Just trying to get a bridge from the 15% to the 8%.
  Response: Increased appreciation for the complexity and duration of organizational change curve led to more prudent guidance; new reps and legacy team need more time to adjust to new structure, comp plan, and territory alignments.

• Question from Michael Sarcone (Jefferies): Can you talk to us about, you know, some of the methods, you know, you plan to use to broaden out that penetration in existing accounts?
  Response: Strategy focuses on driving multiple users per site within key accounts via smaller territories, leveraging full product portfolio (e.g., LIQUIFIX for new surgeons, IHR/LPR for robotic surgery), and academic program support to increase stickiness.

• Question from Matthew O’Brien (Piper Sandler): Maybe just talk about the impact of weather in Q1... and then the what you’re seeing that gives you confidence and should give investors confidence that the back-end loaded guide is achievable.
  Response: Q1 impacted by low January volumes and blizzard-related procedure deferrals; confidence in back-half growth stems from a fully staffed, high-quality sales force, new product launches, and historical ability to snap back after quarters.

• Question from Matthew O’Brien (Piper Sandler): Help me understand, you know, how the different product lines are gonna play out here in 2026.
  Response: Europe (pure OviTex) will drive solid growth; PRS expected to grow from larger pieces and new tech; LIQUIFIX to continue strong growth; overall prudent approach with no signs of business collapse in core segments.

Contradiction Point 1

2026 Full-Year Growth Guidance

Guidance for 2026 growth significantly lowered between Q3 and Q4.

Which company does Caitlin Cronin represent in the earnings call? - Caitlin Cronin (Canaccord Genuity)

2025Q4: The expected quarterly cadence is... and a larger step-up Q3→Q4. This pattern will be amplified by the productivity ramp of the new sales reps hired in late 2025/early 2026. - Roberto Cuca(CFO)

Why is the fiscal year top-line guidance of at least 8% below the previous Q3 guidance, and what is the expected cadence for the year? - Caitlin Cronin (Canaccord Genuity)

20251114-2025 Q3: The 15% growth expectation for full-year 2026 is based on plans for additional sales representative hiring and includes some cushion for potential delays. - Roberto Cuca(CFO)

Contradiction Point 2

Sales Force Hiring and Productivity Timeline

Confidence in new rep productivity timeline contradicts the need for a more cautious, extended ramp-up period.

Michael Sarcone (Jefferies) - Michael Sarcone (Jefferies)

2025Q4: The lower guide provides more time to work through [the transition]. - Jeffrey Blizard(CEO)

What factors contributed to the change from Q3 guidance (at least 15%) to Q4 guidance (at least 8%)—was it increased prudence or other factors? - Frank Takkinen (Lake Street Capital Markets)

20251114-2025 Q3: The faster they can get a bigger cohort of reps onboard, the faster they can drive growth. - Roberto Cuca(CFO)

Contradiction Point 3

Quarterly Revenue Cadence Expectations

Expectation for Q3→Q4 step-up contradicts the Q4 guide implying a larger sequential step-up in Q3→Q4.

Caitlin Cronin (Canaccord Genuity) - Caitlin Cronin (Canaccord Genuity)

2025Q4: The expected quarterly cadence is similar to prior years: a step-up Q1→Q2, a smaller step-up Q2→Q3... and a larger step-up Q3→Q4. - Roberto Cuca(CFO)

Why is the fiscal year top-line guidance of at least 8% below the Q3 call's previous guidance, and what is the expected cadence for the year? - Samantha Munoz (Piper Sandler)

20251114-2025 Q3: The 16% full-year growth guidance accommodates for... which is typically stronger. - Antony Koblish(CEO)

Contradiction Point 4

Nature of Commercial Strategy Changes and Disruption Risk

Characterization of the commercial changes and their disruption risk has shifted from minimal to significant.

Michael Sarcone (Jefferies) - Michael Sarcone (Jefferies)

2025Q4: The reduction in guidance reflects a more accurate appreciation of the change curve required to implement all the commercial changes... The timeline... is longer and more complex than initially thought. - Jeffrey Blizard(President)

What factors led to the decrease in guidance from at least 15% in Q3 to at least 8% in Q4—was it increased prudence or other reasons? - Michael Anthony Sarcone (Jefferies LLC)

2025Q2: Minimal disruption is expected because the team already has the right skill sets... The focus is on shifting the mindset... not on a major overhaul. - Jeffrey Blizard(President)

Contradiction Point 5

Revenue Growth Cadence and Sales Force Stability

Guidance for revenue progression and confidence in execution appears inconsistent.

What were the key drivers of the company's financial performance in the latest quarter? - Caitlin Cronin (Canaccord Genuity)

2025Q4: The expected quarterly cadence is similar to prior years... This pattern will be amplified by the productivity ramp of the new sales reps hired in late 2025/early 2026. - Roberto Cuca(CFO & COO)

Can you explain the decrease in top-line guidance from the Q3 call and provide the cadence for the year? - Caitlin Cronin (Canaccord Genuity Corp.)

2025Q2: The revenue growth pattern is expected to follow the historical seasonal cadence... OpEx is expected to be largely flattish quarter-to-quarter. - Roberto E. Cuca(CFO & COO)